← Back to Search

Monoclonal Antibodies

Erenumab for Facial Pain

Phase 4

Waitlist Available

Led By David Jang, MD

Research Sponsored by David Jang, M.D.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1, 3 and 6 months

Awards & highlights

Study Summary

This trial will test whether Erenumab is effective at reducing midfacial pain or pressure in people without sinusitis.

Eligible Conditions

Facial Pain
Sinusitis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1, 3 and 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1, 3 and 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1, 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in mean number of days per month with significant mid-facial pain or pressure

Secondary outcome measures

Change from baseline in mean daily pain score

Change in Emotional Function

Change in Overall Impact (global)

+7 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ErenumabActive Control1 Intervention

140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.

Group II: PlaceboPlacebo Group1 Intervention

Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

David Jang, M.D.Lead Sponsor

AmgenIndustry Sponsor

1,370 Previous Clinical Trials

1,377,659 Total Patients Enrolled

David Jang, MD4.76 ReviewsPrincipal Investigator - Duke Health

Duke University

5Patient Review

Dr. Jang is extremely knowledgable and kind. He listened to me attentively and described the procedure and every component in detail. He clearly cares a great deal about his patients' well-being and I would recommend him wholeheartedly.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are receiving treatment through this trial?

"Affirmative. Clinicaltrials.gov evidences that this clinical experiment, which was initially published on February 10th 2021, is actively searching for participants. Specifically, 66 patients must be recruited from 1 site to complete the study."

Answered by AI

Has the FDA sanctioned Erenumab for use?

"There is substantial evidence for Erenumab's efficacy, thus it earned a rating of 3 on the safety scale."

Answered by AI

Is recruitment still ongoing for this research endeavour?

"According to clinicaltrials.gov, this medical trial is actively seeking participants. The protocol was first uploaded on February 10th 2021 and underwent its final edit June 23rd 2022."

Answered by AI

Does this medical experiment break new ground?

"Since 2019, Erenumab has been the subject of numerous clinical trials. Initially sponsored by Amgen, an initial 456-person study in 2019 gave way to Phase 3 approval and now there are 18 studies conducted across 179 cities worldwide over 32 countries."

Answered by AI

Are there other documented attempts to utilize Erenumab in research?

"Presently, 18 clinical trials are underway exploring the efficacy of Erenumab with 3 currently in Phase 3. Rochester, Minnesota is home to some of these studies, but 549 different sites have joined the research effort."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Erenumab for Idiosyncratic Facial Pain

David Jang, M.D. 2021. "Erenumab for Idiosyncratic Facial Pain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04249427.